Legacy Wealth Asset Management LLC Reduces Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Legacy Wealth Asset Management LLC reduced its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 8.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 8,112 shares of the medical instruments supplier’s stock after selling 791 shares during the period. Legacy Wealth Asset Management LLC’s holdings in LeMaitre Vascular were worth $747,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in LMAT. NBC Securities Inc. increased its stake in LeMaitre Vascular by 73.2% in the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 183 shares during the last quarter. USA Financial Formulas purchased a new position in shares of LeMaitre Vascular during the third quarter worth approximately $60,000. GAMMA Investing LLC grew its position in shares of LeMaitre Vascular by 34.3% during the third quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock worth $68,000 after acquiring an additional 188 shares during the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of LeMaitre Vascular during the second quarter worth approximately $82,000. Finally, Acadian Asset Management LLC purchased a new position in shares of LeMaitre Vascular during the second quarter worth approximately $104,000. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Trading Up 0.8 %

LeMaitre Vascular stock opened at $99.06 on Friday. The stock has a market cap of $2.23 billion, a PE ratio of 54.13, a P/E/G ratio of 2.07 and a beta of 0.96. The stock has a 50-day moving average price of $98.48 and a 200 day moving average price of $91.80. LeMaitre Vascular, Inc. has a 52 week low of $56.04 and a 52 week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. The firm had revenue of $54.82 million during the quarter, compared to analysts’ expectations of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm’s quarterly revenue was up 15.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.33 EPS. On average, equities analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st were issued a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.65%. The ex-dividend date was Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is 34.97%.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on LMAT shares. Cantor Fitzgerald started coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 target price on the stock. Oppenheimer restated an “outperform” rating and set a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Barrington Research raised their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. Finally, StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $94.57.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of LeMaitre Vascular stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the sale, the director now owns 2,278 shares in the company, valued at $231,148.66. The trade was a 62.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 10.79% of the stock is owned by company insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.